ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BPTH Bio Path Holdings Inc

2.67
-0.015 (-0.56%)
Pre Market
Last Updated: 09:03:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 6,385
Bid Price 2.61
Ask Price 2.67
News -
Day High

Low
2.60

52 Week Range

High
44.80

Day Low
Company Name Stock Ticker Symbol Market Type
Bio Path Holdings Inc BPTH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.015 -0.56% 2.67 09:03:00
Open Price Low Price High Price Close Price Prev Close
2.685
Trades Volume Avg Volume 52 Week Range
97 6,385 - 2.60 - 44.80
Last Trade Time Type Quantity Stock Price Currency
09:07:01 88 $ 2.61 USD

Bio Path Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.82M 678.80k - 0 -16.08M -23.69 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Bio Path News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BPTH Message Board. Create One! See More Posts on BPTH Message Board See More Message Board Posts

Historical BPTH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.127.66992.604.1817,404,772-0.45-14.42%
1 Month4.147.66992.604.174,603,504-1.47-35.51%
3 Months8.229.98752.604.311,572,665-5.55-67.52%
6 Months12.50414.4242.605.03812,324-9.83-78.65%
1 Year28.0044.802.6010.661,152,050-25.33-90.46%
3 Years123.00172.3982.6040.18528,048-120.33-97.83%
5 Years362.00486.802.6093.08526,906-359.33-99.26%

Bio Path Description

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.

Your Recent History

Delayed Upgrade Clock